Literature DB >> 2788196

Use of beta-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization.

F Léonard1, A Andremont, B Leclerq, R Labia, C Tancrède.   

Abstract

Six adult volunteers were given 1 g/d of intravenous ceftriaxone for 5 d (consecutive). Ceftriaxone and beta-lactamase activities were assayed in fecal samples obtained before and during drug administration, and anaerobic bacteria, Enterobacteriaceae, and fungi were counted. In two volunteers, no fecal beta-lactamase activity was detected, but ceftriaxone was present during treatment at concentrations of 1.8-2.0 mg/g of feces. Concomitantly, fecal counts of anaerobes in these volunteers dropped from 10.5 to less than 8 log10 colony-forming units (cfu)/g of feces, and those of Candida species increased more than 100-fold. However, in the feces of the four other volunteers, beta-lactamase activity was high during ceftriaxone administration, but no ceftriaxone was detected. In these volunteers, ceftriaxone administration was not followed by any significant change in counts of anaerobes or Candida species. This appeared to be due to the intraintestinal hydrolysis of ceftriaxone by resident beta-lactamase-producing anaerobes. In gnotobiotic mice associated with a human fecal flora containing no beta-lactamase-producing anaerobes, it was possible to prevent the deleterious effects of ceftriaxone on intestinal microbial composition and on colonization resistance (against a strain of Candida albicans and one of ceftriaxone-resistant Enterobacter cloacae) by feeding the animals with an association of four beta-lactamase-producing anaerobic strains.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788196     DOI: 10.1093/infdis/160.2.274

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens.

Authors:  Charles Burdet; Nathalie Grall; Morgane Linard; Antoine Bridier-Nahmias; Michèle Benhayoun; Khadija Bourabha; Mélanie Magnan; Olivier Clermont; Camille d'Humières; Olivier Tenaillon; Erick Denamur; Laurent Massias; Sarah Tubiana; Loubna Alavoine; Antoine Andremont; France Mentré; Xavier Duval
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  The effect of ceftriaxone on the anaerobic bacterial flora and the bacterial enzymatic activity in the intestinal tract.

Authors:  G W Welling; G J Meijer-Severs; G Helmus; E van Santen; R H Tonk; H G de Vries-Hospers; D van der Waaij
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

Review 3.  Role of human microflora in health and disease.

Authors:  C Tancrède
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

4.  Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.

Authors:  Mark J DiNubile; Joseph W Chow; Vilas Satishchandran; Adam Polis; Mary R Motyl; Murray A Abramson; Hedy Teppler
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Gastrointestinal colonization with a cephalosporinase-producing bacteroides species preserves colonization resistance against vancomycin-resistant enterococcus and Clostridium difficile in cephalosporin-treated mice.

Authors:  Usha Stiefel; Michelle M Nerandzic; Michael J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

6.  Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II study.

Authors:  M Mego; R Koncekova; E Mikuskova; L Drgona; L Ebringer; L Demitrovicova; I Nemova; J Trupl; J Mardiak; I Koza; V Zajac
Journal:  Support Care Cancer       Date:  2005-09-21       Impact factor: 3.603

7.  Induction of beta-lactamase by cefoxitin in anaerobic intestinal microflora.

Authors:  C Stark; C Edlund; M Hedberg; C E Nord
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-01       Impact factor: 3.267

Review 8.  Colonization resistance.

Authors:  E J Vollaard; H A Clasener
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.

Authors:  S Faure; A Perrin-Guyomard; J M Delmas; P Chatre; M Laurentie
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

10.  Shedding of Clostridium difficile, fecal beta-lactamase activity, and gastrointestinal symptoms in 51 volunteers treated with oral cefixime.

Authors:  E Chachaty; C Bourneix; S Renard; M Bonnay; A Andremont
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.